{"id":1758,"date":"2017-01-03T12:30:18","date_gmt":"2017-01-03T12:30:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1758"},"modified":"2021-07-24T12:56:37","modified_gmt":"2021-07-24T07:26:37","slug":"notizia-20","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-20","title":{"rendered":"Sanofi sues Novo; Allergan gets help; Actelion snubs; Impax CEO Wilkinson out"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e44983889c7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e44983889c7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-20\/#Sanofi_sues_Novo_over_%E2%80%98misleading_Tresiba_marketing_materials\" >Sanofi sues Novo over &#8216;misleading&#8217; Tresiba marketing materials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-20\/#Acquisitive_Allergan_gets_top-line_help_cost-savings_potential_with_29B_LifeCell_buy\" >Acquisitive Allergan gets top-line help, cost-savings potential with $2.9B LifeCell buy<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-20\/#Actelion_snubs_Sanofi_and_restarts_talks_with_J_J\" >Actelion snubs Sanofi and restarts talks with J&amp;J<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-20\/#Impax_CEO_Wilkinson_out_as_company_searches_for_new_leadership\" >Impax CEO Wilkinson out as company searches for new leadership<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Sanofi_sues_Novo_over_%E2%80%98misleading_Tresiba_marketing_materials\"><\/span>Sanofi sues Novo over &#8216;misleading&#8217; Tresiba marketing materials<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sanofi has sued Novo over the Danish drugmaker\u2019s marketing materials for Tresiba, alleging that they falsely claimed Sanofi\u2019s competing products\u2014blockbuster Lantus and follow-up Toujeo\u2014won\u2019t be available to many U.S. patients down the line. The pharma giant is seeking an order to force Novo to pay unspecified money damages and pull the materials in question. According to Sanofi\u2019s complaint, filed in U.S. District Court for the District of New Jersey, the materials urged doctors and patients to make the change in treatment because Sanofi\u2019s meds would supposedly be \u201cblocked\u201d in January.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Acquisitive_Allergan_gets_top-line_help_cost-savings_potential_with_29B_LifeCell_buy\"><\/span>Acquisitive Allergan gets top-line help, cost-savings potential with $2.9B LifeCell buy<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Dublin drug maker has inked a pact to pick up regenerative medicine player LifeCell for $2.9 billion in cash. LifeCell racked up about $450 million in 2016 revenue that\u2019ll boost Allergan\u2019s own top line going forward, and it\u2019s expanding at a mid-single digit rate. The addition of LifeCell\u2019s product line\u2014which includes human allograft tissue matrix AlloDerm, fat-grafting device Revolve and procine-based tissue matrix Strattice\u2014will help Allergan create a world-class aesthetic and regenerative medicine business providing significant opportunity to enhance the overall product offering for plastic and general surgery customers globally.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Actelion_snubs_Sanofi_and_restarts_talks_with_J_J\"><\/span>Actelion snubs Sanofi and restarts talks with J&amp;J<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Swiss drugmaker Actelion is back at the negotiating table with Johnson &amp; Johnson, appearing to have given Sanofi the cold shoulder just as the French drugmaker was thought to have figured out how to bring the biotech to ground. While investors were hoping for culmination of a deal before Christmas, a source pointed that it is &#8220;neither impossible nor unusual&#8221; to see big deals finally tied up around Christmas and New Year&#8217;s Eve.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Impax_CEO_Wilkinson_out_as_company_searches_for_new_leadership\"><\/span>Impax CEO Wilkinson out as company searches for new leadership<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Under a \u201cmutual agreement\u201d with the board, Impax CEO Fred Wilkinson is departing the company, to be replaced by board member J. Kevin Buchi on an interim basis. The move comes as the company\u2019s stock has steadily drifted down in recent years and now is trading at its lowest point since 2010. Wilkinson will depart after more than two years at the California-based generic and specialty Pharma Company. Buchi, who only joined the board last month, will serve until Impax can find a permanent leader. Buchi currently serves as CEO at TetraLogic Pharmaceuticals, where he&#8217;s expected to step down by the end of the year.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi sues Novo over &#8216;misleading&#8217; Tresiba marketing materials Sanofi has sued Novo over the Danish drugmaker\u2019s marketing materials for Tresiba, alleging that they falsely claimed Sanofi\u2019s competing products\u2014blockbuster Lantus and follow-up Toujeo\u2014won\u2019t be available to many U.S. patients down the line. The pharma giant is seeking an order to force Novo to pay unspecified money [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1712,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[731,420,730,712],"industry":[17225],"therapeutic_areas":[17235,17240],"class_list":["post-1758","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-deals","tag-news","tag-notizia","tag-pharma-industry","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sanofi sues Novo; Allergan gets help; Actelion snubs<\/title>\n<meta name=\"description\" content=\"Sanofi has sued Novo over the Danish drugmaker\u2019s marketing materials for Tresiba, alleging that they falsely claimed Sanofi\u2019s competing products...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-20\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sanofi sues Novo; Allergan gets help; Actelion snubs\" \/>\n<meta property=\"og:description\" content=\"Sanofi has sued Novo over the Danish drugmaker\u2019s marketing materials for Tresiba, alleging that they falsely claimed Sanofi\u2019s competing products...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-20\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-01-03T12:30:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"343\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sanofi sues Novo; Allergan gets help; Actelion snubs","description":"Sanofi has sued Novo over the Danish drugmaker\u2019s marketing materials for Tresiba, alleging that they falsely claimed Sanofi\u2019s competing products...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-20","og_locale":"en_US","og_type":"article","og_title":"Sanofi sues Novo; Allergan gets help; Actelion snubs","og_description":"Sanofi has sued Novo over the Danish drugmaker\u2019s marketing materials for Tresiba, alleging that they falsely claimed Sanofi\u2019s competing products...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-20","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-01-03T12:30:18+00:00","article_modified_time":"2021-07-24T07:26:37+00:00","og_image":[{"width":960,"height":343,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-20","url":"https:\/\/www.delveinsight.com\/blog\/notizia-20","name":"Sanofi sues Novo; Allergan gets help; Actelion snubs","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-20#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-20#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","datePublished":"2017-01-03T12:30:18+00:00","dateModified":"2021-07-24T07:26:37+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Sanofi has sued Novo over the Danish drugmaker\u2019s marketing materials for Tresiba, alleging that they falsely claimed Sanofi\u2019s competing products...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-20"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-20#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news.jpg","width":960,"height":343},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/12\/09021232\/news-300x107.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Deals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Deals<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 3, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 3, 2017 12:30 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1758"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1758\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1712"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1758"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1758"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}